drugset / Trial / NCT05178888
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and clinical activity of MRTX849 (adagrasib) in combination with palbociclib in patients with advanced solid tumor malignancies with KRAS G12C mutation.
Timeline
- Start
- 2022-01-20
- Primary completion
- 2023-06-15
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adagrasib | Small molecule | — | Oral |
| Subject | Palbociclib | Small molecule | — | — |